SCHEMBL7762520

SCHEMBL7762520

COc1cccc(-c2ccc(OC)c3nc(NC(=O)c4ccc(C)s4)nn23)c1

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.48
SMN1; SMN2 Q16637 3/20 0.46
PDE4D Q08499 10/20 0.44
KDM4E B2RXH2 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
MEN1 O00255 1/20 0.41
HPGD P15428 1/20 0.41
MAPK1 P28482 1/20 0.41
CCR6 P51684 1/20 0.41
KMT2A Q03164 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MAPT P10636 3/20 0.40
PIK3CG P48736 1/20 0.39
FYN P06241 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7044503 0.92 HPGD (0.43) JAK2SMN1; SMN2PDE4DKDM4EHPGD
SCHEMBL7766251 0.92 SMN1; SMN2 (0.47) JAK2SMN1; SMN2PDE4DHPGDMAPK1
SCHEMBL7762456 0.90 SMN1; SMN2 (0.45) JAK2SMN1; SMN2PDE4DKMT2AMAPT
SCHEMBL6871450 0.90 SMN1; SMN2 (0.45) JAK2SMN1; SMN2PDE4DKDM4EHPGD
SCHEMBL7146644 0.90 SMN1; SMN2 (0.53) SMN1; SMN2PDE4DKDM4ENPC1RAB9A
SCHEMBL7762663 0.89 PDE4D (0.57) SMN1; SMN2PDE4DNPC1MAPTFYN
SCHEMBL7766283 0.89 FYN (0.47) SMN1; SMN2PDE4DKDM4EFYN
SCHEMBL7765386 0.88 JAK2 (0.45) JAK2SMN1; SMN2PDE4DKDM4EHPGD
SCHEMBL7142931 0.86 PDE4D (0.51) SMN1; SMN2PDE4DKDM4ENPC1RAB9A
SCHEMBL7765412 0.86 SMN1; SMN2 (0.47) SMN1; SMN2PDE4DKDM4ENPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6514989-B1 Has a good affinity to the adenosine receptor and can therefore be used for the treatment or protection of diseases mediated by this receptor HOFFMANN-LA ROCHE INC. 2003-02-04 US disclosed
US-6514989-B1 Has a good affinity to the adenosine receptor and can therefore be used for the treatment or protection of diseases mediated by this receptor HOFFMANN-LA ROCHE INC. 2003-02-04 US disclosed